ArticleCurrent medical science2025
Inflammation-Related Factors S100A9 and TLR2 in Cardiomyocyte Hypertrophy.
Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Toll-like receptors in infectious myocarditis: pathogen-specific recognition, spatiotemporal dynamic regulation and clinical translation.Frontiers in cardiovascular medicine · 2026Review
- Identification of the Hub genes and inhibitors associated with hypertension in children with obesity using WGCNA.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe pathogenesis and progression of heart failure (HF) are governed by complex, interconnected biological pathways, with dysregulated immune responses and maladaptive cardiac remodeling playing central roles. Although specific inflammatory mediators have been implicated in modulating critical features of cardiac remodeling-such as cardiomyocyte hypertrophy and extracellular matrix fibrosis-the precise molecular mechanisms driving these processes remain incompletely characterized.
methodsIntegrated bioinformatics analysis of HF and hypertrophic cardiomyopathy (HCM) transcriptomic datasets identified pathologically relevant candidate genes. A protein-protein interaction (PPI) network was constructed from these candidates using the STRING database, followed by module analysis. Serum S100 calcium-binding protein A9 (S100A9) protein expression in HF patients was quantified by Western blotting under reducing conditions. The functional relevance of prioritized genes was subsequently validated through: (i) in vitro cyclic mechanical stretch in primary neonatal rat cardiomyocytes, and (ii) in vivo pressure overload modeling via transverse aortic constriction (TAC) in mice.
resultsBioinformatics analysis of HF and HCM datasets revealed a significant association between immune function and cardiac remodeling. Using CytoNCA, we identified core genes, among which the top 25 included multiple inflammatory pathway-related factors, such as S100A9 and Toll-like receptor 2 (TLR2). Notably, S100A9 levels were significantly elevated in the serum of HF patients and in mechanically stretched cardiomyocytes. This increase correlated with upregulated expression of hypertrophy-related markers, including atrial natriuretic peptide (ANP). Furthermore, mechanical stretch-induced S100A9 upregulation markedly enhanced TLR2 expression in cardiomyocytes. Importantly, TLR2 inhibition substantially attenuated the mechanical stretch-induced upregulation of S100A9 mRNA expression, as well as the subsequent hypertrophic and inflammatory responses in cardiomyocytes.
conclusionThe inflammatory mediators S100A9 and TLR2 engage in reciprocal activation that amplifies the hypertrophic response in mechanically stretched cardiomyocytes. This pathogenic cross-talk exacerbates maladaptive remodeling and likely accelerates HF progression.
Indexed as
Identifiers
40694254What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.